International Journal of Medical and Pharmaceutical Research

Online ISSN-2958-3683 | Print ISSN-2958-3675
Frequency: Bi-Monthly
Available online on: https://ijmpr.in/

Review Article

Emerging Role of GLP-1 and Dual Incretin Agonists in the Management of Type 2 Diabetes Mellitus: Mechanisms, Clinical Evidence, Dosing Strategies, and Future Perspectives

Amar M. Raval[1]*, Krina N Chaudhari[2], Dr. Bhoomi Arora[3], Dr. Aastha Ukani[4], Riddhi Modh[5] Dr. Kuldeep Choubisa[6], Dr. Ashok Kumar[7]

[1] Associate Professor, Department of Pharmaceutics
Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India. ***ORCID: 0009-0005-1409-1745***
[2] Assistant Professor, Department of Pharmacology, Sharda School of Pharmacy
Pethapur, Gandhinagar, Gujarat, India. ***ORCID: 0009-0000-2123-9262***
[3] Professor & Head, Department of Pharmacology
K. B. Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat, India. ***ORCID: 0000-0002-8363-6439***
[4] Assistant Professor, Department of Pharmacy Practice, Sharda School of Pharmacy
Pethapur, Gandhinagar, Gujarat, India. ***ORCID: 0009-0006-0536-362X***
[5] Assistant Professor, Department of Pharmaceutical Quality Assurance
Saraswati Institute of Pharmaceutical Sciences, Dhanap, Gandhinagar, Gujarat, India. ***ORCID: 0009-0002-9737-334X***
[6] Assistant Professor, Department of Pharmacy Practice (Pharm.D)
Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India. ***ORCID: 0009-0002-9455-6757***
[7] Assistant Professor & Head, Department of Pharmacy Practice (Pharm.D)
Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India. ***ORCID: 0009-0009-0295-1807***

OPEN ACCESS

Corresponding Author:

Amar M. Raval
Associate Professor
Department of Pharmaceutics
Sharda School of Pharmacy
Pethapur, Gandhinagar
Gujarat-382610, India
ORCID: 0009-0005-1409-1745

Received: 20-02-2026
Accepted: 30-04-2026
Available online: 13-05-2026

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, β-cell dysfunction, and impaired incretin response. Conventional therapies often fail to provide sustained glycemic control and do not address the multifactorial pathogenesis of the disease. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists such as Tirzepatide, have emerged as transformative agents in diabetes management. These therapies exert pleiotropic effects, including glucose-dependent insulin secretion, suppression of glucagon, delayed gastric emptying, and central appetite regulation. Recent clinical trials (SURPASS, STEP) demonstrate superior glycemic control and significant weight reduction with dual incretin agonists compared to GLP-1 monotherapy and insulin-based regimens. Additionally, these agents provide cardiovascular and renal protection, positioning them as first-line therapies in modern diabetes guidelines. This review provides a comprehensive analysis of incretin physiology, pharmacology, clinical outcomes, dosing strategies, safety, and future directions, highlighting their role as cornerstone therapies in T2DM management.

Keywords*: Type 2 diabetes mellitus, incretin-based therapy, glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic polypeptide, dual incretin agonist, Tirzepatide, Semaglutide, insulin resistance, glycemic control, obesity, cardiovascular outcomes, weight reduction, metabolic syndrome, precision medicine, diabetic complications,*

1. INTRODUCTION

Diabetes mellitus is one of the most challenging global health problems of the 21st century. According to recent estimates, more than 537 million adults are currently living with diabetes, with projections reaching 783 million by 2045. Type 2 diabetes mellitus (T2DM) accounts for approximately 90-95% of all diabetes cases [1].

1.1 India represents a major epicenter of T2DM due to:

- Genetic predisposition
- Urban lifestyle changes
- Sedentary behavior
- High carbohydrate diet

Traditional therapies such as metformin, sulfonylureas, and insulin primarily target hyperglycemia but fail to address underlying metabolic dysregulation.

This limitation led to the development of incretin-based therapies, which act on multiple physiological pathways simultaneously [2].

1.2 EPIDEMIOLOGY (EXPANDED)

Parameter	Value
Global prevalence	>537 million
India prevalence	>77 million
Projected (2045)	~783 million
Mortality	~6.7 million/year

1.3 Key Risk Factors:

- Obesity
- Sedentary lifestyle
- Genetic predisposition
- Aging population

The increasing burden highlights the need for **multifunctional therapies like GLP-1 agonists**.

1.4 PATHOPHYSIOLOGY OF T2DM

T2DM is no longer viewed as a simple disorder of insulin deficiency but rather a **multi-organ metabolic disease**.

1.4.1 The "Ominous Octet" Concept [3]

Proposed by DeFronzo, includes:

1. Pancreatic β-cell dysfunction
2. Pancreatic α-cell dysfunction
3. Increased hepatic glucose production
4. Neurotransmitter dysfunction
5. Increased lipolysis
6. Reduced glucose uptake (muscle)
7. Increased renal glucose reabsorption
8. Reduced incretin effect

Reduced incretin effect is central to disease progression [4]

1.4.2 Insulin Resistance Mechanism

- Decreased GLUT-4 activity
- Increased free fatty acids
- Chronic inflammation

1.4.3 β-Cell Dysfunction

- Glucotoxicity
- Lipotoxicity
- Oxidative stress

1.4.4 Incretin Defect [5]

In healthy individuals:
Oral glucose → high insulin response
In T2DM:

Reduced GLP-1 activity
Impaired insulin secretion
This defect is directly targeted by incretin therapy.

1.5. INCRETIN PHYSIOLOGY [6-10]
1.5.1 Incretin Effect (Scientific Basis)
The incretin effect refers to enhanced insulin secretion after oral glucose intake compared to intravenous glucose.
Main hormones:

- GLP-1
- GIP

1.5.2 GLP-1 STRUCTURE & SECRETION

- Secreted from intestinal L-cells
- Released after food intake
- Rapidly degraded by DPP-4 enzyme

1.5.3 GLP-1 RECEPTOR DISTRIBUTION

- Pancreas
- Brain
- Heart
- Kidney
- GI tract

Explains **multi-organ effects**

1.5.4 MECHANISM OF GLP-1 ACTION [11]
Cellular Mechanism:

1. GLP-1 binds receptor
2. Activates adenylate cyclase
3. ↑ cAMP
4. Activates PKA
5. Insulin granule exocytosis

1.5.5 PHYSIOLOGICAL EFFECTS

Effect	Mechanism
Insulin secretion	Glucose-dependent
Glucagon suppression	α-cell inhibition
Gastric emptying ↓	GI motility
Appetite ↓	CNS (hypothalamus)

1.5.6 GIP MECHANISM

- Enhances insulin secretion
- Promotes fat metabolism
- Works synergistically with GLP-1

1.5.7 DUAL INCRETIN ACTION
Tirzepatide works via:

- GLP-1 receptor → glucose control
- GIP receptor → metabolic enhancement

Result:
Greater HbA1c reduction
Significant weight loss
Improved insulin sensitivity

1.5.8 MOLECULAR SIGNALING PATHWAYS [12]
GLP-1 Pathways:

- cAMP-PKA pathway
- PI3K-AKT pathway
- MAPK signaling

Outcomes:

- β-cell survival
- Reduced apoptosis
- Improved insulin biosynthesis



Figure 1: Mechanism of GLP-1 and Dual Incretin Agonists

1.6 Pharmacological Basis of Incretin-Based Therapies

Incretin-based therapies have been developed to overcome the limitations of endogenous incretin hormones, particularly their rapid degradation by dipeptidyl peptidase-4 (DPP-4). These therapies are broadly classified into two major categories: GLP-1 receptor agonists (GLP-1 RAs) and dual incretin receptor agonists[13].

GLP-1 receptor agonists are structurally modified peptides designed to resist enzymatic degradation, thereby prolonging their half-life and enhancing therapeutic efficacy. Dual incretin agonists, on the other hand, simultaneously target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering synergistic metabolic effects[14].

1.6.1 Classification of Incretin-Based Therapies[15]

1.6.1.1 GLP-1 Receptor Agonists

GLP-1 receptor agonists are classified based on duration of action:

Short-acting agents:

- Exenatide (twice daily)
- Lixisenatide (once daily)

Long-acting agents:

- Liraglutide (once daily)
- Dulaglutide (once weekly)
- Semaglutide (once weekly/oral)

Long-acting agents provide sustained receptor activation and superior glycemic control compared to short-acting formulations [16].

1.6.1.2 Dual Incretin Agonists

- Tirzepatide

Tirzepatide represents the first-in-class dual incretin agonist and has demonstrated enhanced efficacy due to combined receptor activation [17].

1.7 Mechanistic Comparison of Incretin Therapies

Mechanism	GLP-1 Agonists	Dual Agonists
Insulin secretion	Increased	Strongly increased
Glucagon suppression	Yes	Yes
Weight loss	Moderate	Significant
Insulin sensitivity	Mild	High
Appetite suppression	Strong	Very strong

Dual incretin agonists exhibit superior metabolic effects due to synergistic receptor activity [6,7].

1.8. Dosing Strategies and Administration

1.8.1 GLP-1 Receptor Agonists

Drug	Starting Dose	Maintenance Dose	Route
Liraglutide	0.6 mg/day	1.2-1.8 mg/day	SC
Semaglutide	0.25 mg/week	0.5-1 mg/week	SC
Dulaglutide	0.75 mg/week	1.5 mg/week	SC

Oral formulation:

- Semaglutide: 3 mg → 7 mg → 14 mg daily

1.8.2 Dual Incretin Agonist

Drug	Starting Dose	Maximum Dose	Route
Tirzepatide	2.5 mg/week	15 mg/week	SC

Dose escalation is recommended to minimize gastrointestinal adverse effects [18].

1.9. Pharmacokinetics of GLP-1 Receptor Agonists

1.9.1 Absorption

- Administered subcutaneously
- Slow absorption with peak plasma levels within 24-72 hours

1.9.2 Distribution

- High protein binding
- Distributed to pancreas, CNS, and peripheral tissues

1.9.3 Metabolism

- Resistant to DPP-4 degradation
- Metabolized via proteolytic pathways

1.9.4 Elimination

- Primarily renal and proteolytic clearance

1.10. Pharmacokinetics of Dual Incretin Agonists

Tirzepatide demonstrates:

- Long half-life (~5 days)
- Once-weekly dosing
- Stable plasma concentration

This pharmacokinetic profile contributes to improved patient adherence and therapeutic outcomes [19].

1.11. Comparative Pharmacological Advantages

Parameter	GLP-1 RAs	Dual Agonists
Half-life	Moderate	Long
Dosing frequency	Daily/Weekly	Weekly
HbA1c reduction	Moderate	High
Weight loss	Moderate	Very high

1.12. Drug Interactions and Clinical Considerations

- Delayed gastric emptying may affect oral drug absorption
- Minimal risk of hypoglycemia unless combined with insulin or sulfonylureas
- Dose adjustment may be required in renal impairment [20].

1.13. Special Populations

1.13.1 Elderly Patients

- Well tolerated
- Lower risk of hypoglycemia

1.13.2 Renal Impairment

- Most GLP-1 RAs are safe
- Monitoring recommended

1.13.3 Obese Patients

- Preferred due to weight reduction benefits

1.14. Summary of Pharmacological Profile

Incretin-based therapies offer:

- Prolonged action
- Multi-targeted metabolic effects
- Favorable safety profile

Dual incretin agonists represent a significant advancement due to enhanced efficacy and improved pharmacokinetics[21].

1.15. Overview of Clinical Evidence

The clinical development of incretin-based therapies has been supported by multiple large-scale randomized controlled trials (RCTs) evaluating glycemic control, weight reduction, cardiovascular outcomes, and safety. Among these, the **SURPASS** (tirzepatide) and **STEP** (semaglutide) programs represent the most comprehensive evidence base for incretin therapies.

These trials consistently demonstrate that GLP-1 receptor agonists and dual incretin agonists provide superior metabolic benefits compared to conventional therapies, including insulin and oral hypoglycemic agents [22].

2. SURPASS Clinical Trial Program (Tirzepatide)

The SURPASS program consists of multiple phase III trials evaluating the efficacy and safety of Tirzepatide in patients with type 2 diabetes [23].

2.1 Summary of SURPASS Trials

Trial	Comparator	Key Outcome
SURPASS-1	Placebo	HbA1c ↓ up to 2.07%
SURPASS-2	Semaglutide	Superior HbA1c reduction
SURPASS-3	Insulin degludec	Better glycemic control
SURPASS-4	Insulin glargine	CV risk reduction
SURPASS-5	Insulin + tirzepatide	Add-on benefit

2.2 Key Findings

- HbA1c reduction: up to **2.3%**
- Weight reduction: up to **20% body weight**
- Significant improvement in insulin sensitivity
- Reduced cardiovascular risk markers

These results highlight the **superiority of dual incretin therapy** over both GLP-1 monotherapy and insulin [24].

2.3 STEP Clinical Trial Program (Semaglutide)

The STEP trials evaluate the role of Semaglutide in obesity and diabetes management.

2.4 Summary of STEP Trials

Trial	Population	Outcome
STEP-1	Obesity (non-diabetic)	Weight ↓ ~15%
STEP-2	T2DM patients	HbA1c ↓ 1.6%
STEP-3	Lifestyle + drug	Enhanced weight loss
STEP-4	Maintenance	Sustained weight reduction

2.4.1 Clinical Implications

- Demonstrates role beyond glycemic control
- Effective for obesity management
- Long-term sustainability of weight loss

3. Cardiovascular Outcome Trials (CVOTs)

GLP-1 receptor agonists have demonstrated significant cardiovascular benefits in large outcome trials [25].

3.1 Major CVOT Studies

Trial	Drug	Outcome
LEADER	Liraglutide	↓ CV mortality
SUSTAIN-6	Semaglutide	↓ MACE
REWIND	Dulaglutide	CV protection

3.2 Key Cardiovascular Benefits

- Reduction in major adverse cardiovascular events (MACE)
- Improved endothelial function
- Anti-inflammatory effects

These findings support the use of incretin therapies in patients with high cardiovascular risk [26].

4. Real-World Evidence (RWE)

Real-world studies complement clinical trials by evaluating effectiveness in broader patient populations.

4.1 Observational Study Findings

- Improved glycemic control in routine clinical practice
- Better adherence with once-weekly formulations
- Reduced hospitalization rates

4.2 Comparative Effectiveness

Parameter	GLP-1 RA	Dual Agonist
HbA1c reduction	Moderate	High
Weight loss	Moderate	Very high
Adherence	High	Very high

Real-world data confirm the **translatability of clinical trial outcomes into practice** [27].

5. Case Studies (Clinical Application)

5.1 Case Study 1: Uncontrolled T2DM with Obesity

Patient Profile:

- Age: 52 years
- BMI: 34 kg/m²
- HbA1c: 9.2%
- Previous therapy: Metformin + sulfonylurea

Intervention:

- Initiation of Tirzepatide

Outcome (24 weeks):

- HbA1c reduced to 6.8%
- Weight loss: 12 kg
- Improved lipid profile

Conclusion:

Dual incretin therapy demonstrated superior metabolic control.

5.2 Case Study 2: Cardiovascular Risk Patient

Patient Profile:

- Age: 60 years
- History: T2DM + coronary artery disease
- HbA1c: 8.5%

Intervention:

- Initiation of Liraglutide

Outcome:

- HbA1c reduction to 7.1%
- Reduced cardiovascular risk markers

5.3 Case Study 3: Obesity without Diabetes

Patient Profile:

- BMI: 36 kg/m²
- Non-diabetic

Intervention:

- Semaglutide

Outcome:

- Weight reduction: 15%
- Improved metabolic parameters



Figure 2: Case studies

6. Comparative Efficacy Analysis

Outcome	GLP-1 RAs	Tirzepatide
HbA1c reduction	1-1.5%	>2%
Weight loss	5-10%	15-20%
CV benefit	Proven	Emerging strong evidence

6.1. Summary of Clinical Evidence [28]

- GLP-1 receptor agonists provide robust glycemic and cardiovascular benefits
- Dual incretin agonists demonstrate superior efficacy
- Clinical trial results are supported by real-world evidence
- Expanding role in obesity and metabolic disorders

6.2 Overview of Safety Considerations

Incretin-based therapies, including GLP-1 receptor agonists and dual incretin agonists such as Tirzepatide, are generally well tolerated and exhibit a favorable safety profile compared to traditional antidiabetic therapies. Their glucose-dependent mechanism of action significantly reduces the risk of hypoglycemia, making them suitable for a wide range of patients.

However, like all pharmacological agents, these therapies are associated with specific adverse effects, contraindications, and clinical considerations that must be carefully evaluated [29].

6.3. Common Adverse Effects

The most frequently reported adverse effects are gastrointestinal in nature and are primarily dose-dependent.

6.4 Gastrointestinal Effects

Adverse Effect	Incidence	Mechanism
Nausea	Very common	Delayed gastric emptying
Vomiting	Common	Central satiety effect
Diarrhea	Common	GI motility alteration
Constipation	Occasional	Reduced gastric motility

These effects are typically transient and occur during the initiation or dose-escalation phase. Gradual dose titration significantly improves tolerability [30].

6.5 Hypoglycemia Risk

GLP-1 receptor agonists have a **low intrinsic risk of hypoglycemia** due to their glucose-dependent insulinotropic action.

Risk increases when combined with:

- Insulin
- Sulfonylureas

Clinical Recommendation:

Dose adjustment of concomitant hypoglycemic agents is advised when initiating incretin therapy.

7. Serious and Rare Adverse Effects

Although uncommon, certain serious adverse events have been reported.

7.1 Acute Pancreatitis

- Rare but clinically significant
- Symptoms: severe abdominal pain, nausea
- Mechanism: not fully understood

Clinical Guidance:

Therapy should be discontinued if pancreatitis is suspected.

7.2 Gallbladder Disease

- Increased risk of cholelithiasis and cholecystitis
- Associated with rapid weight loss

7.3 Thyroid C-Cell Tumors

- Observed in rodent studies
- No conclusive evidence in humans

Contraindicated in:

- Medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN2)

8. Safety of Dual Incretin Agonists

Tirzepatide demonstrates a safety profile similar to GLP-1 receptor agonists, with slightly higher gastrointestinal adverse effects due to enhanced receptor activity [31].

9. Drug Interactions

9.1 Pharmacokinetic Interactions

- Delayed gastric emptying may affect absorption of oral medications

Affected drugs include:

- Oral contraceptives
- Antibiotics
- Thyroid medications

9.2 Pharmacodynamic Interactions

Drug Class	Interaction
Insulin	Increased hypoglycemia risk
Sulfonylureas	Additive glucose-lowering effect
SGLT2 inhibitors	Synergistic benefit

10. Contraindications

Absolute Contraindications:

- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Hypersensitivity to drug components

Relative Contraindications:

- Severe gastrointestinal disease
- History of pancreatitis

11. Use in Special Populations

11.1 Elderly Patients
- Generally safe
- Lower hypoglycemia risk
- Monitor for gastrointestinal intolerance

11.2 Renal Impairment
- Most GLP-1 RAs can be used safely
- Dose adjustment may be required

11.3 Hepatic Impairment
- Limited data available
- Use with caution

11.4 Pregnancy and Lactation
- Limited safety data
- Not routinely recommended

12. Long-Term Safety Considerations

Long-term studies indicate:
- Sustained weight loss
- Cardiovascular safety
- No significant increase in cancer risk

However, continued pharmacovigilance is required for newer agents[32].

13. Limitations of Incretin-Based Therapies

Despite their advantages, several limitations exist:

13.1 Cost
- High cost limits accessibility, especially in low- and middle-income countries

13.2 Route of Administration
- Injectable formulations may reduce patient acceptance

13.3 Gastrointestinal Intolerance
- Major cause of treatment discontinuation

13.4 Long-Term Data
- Limited long-term safety data for dual and triple agonists

14. Risk-Benefit Analysis

Parameter	Benefit	Risk
Glycemic control	High	Minimal
Weight loss	Significant	GI effects
CV protection	Strong	Rare adverse events
Hypoglycemia	Low	Increased with combination

Overall, the benefit-risk profile strongly favors incretin-based therapies in appropriate patient populations [33].

15. Clinical Management Strategies

To optimize safety:
- Gradual dose titration
- Patient education on GI effects
- Monitoring for pancreatitis symptoms
- Adjusting concomitant medications

16. Summary of Safety Profile
- Favorable safety profile compared to traditional therapies
- Low hypoglycemia risk
- Gastrointestinal effects are most common but manageable
- Rare serious adverse events require clinical vigilance

17. Emerging Trends in Incretin-Based Therapy

The rapid evolution of incretin-based therapies has opened new avenues for the treatment of type 2 diabetes mellitus (T2DM) and related metabolic disorders. While GLP-1 receptor agonists and dual incretin agonists such as Tirzepatide have already demonstrated significant clinical success, ongoing research is focused on enhancing efficacy, improving patient compliance, and expanding therapeutic applications [34].

18. Triple Receptor Agonists

A major advancement in incretin pharmacotherapy is the development of **triple receptor agonists**, which simultaneously target:

- GLP-1 receptor
- GIP receptor
- Glucagon receptor

These agents aim to provide:

- Enhanced weight reduction
- Improved glycemic control
- Increased energy expenditure

Preclinical and early clinical studies suggest that triple agonists may surpass dual incretin therapies in metabolic outcomes [35].

19. Oral and Non-Invasive Formulations

One of the key limitations of current incretin therapies is their injectable route of administration. The development of oral formulations represents a significant advancement.

Key Developments:

- Oral semaglutide with absorption enhancers
- Transdermal delivery systems
- Implantable drug delivery devices

These innovations are expected to improve patient adherence and accessibility [36].

20. Precision Medicine and Personalized Therapy

The integration of precision medicine into diabetes care is an emerging trend. Individual variability in response to incretin therapy has led to interest in personalized treatment approaches.

Key Factors:

- Genetic polymorphisms
- Metabolic phenotype
- Gut microbiome composition

Future therapeutic strategies may involve tailoring incretin therapy based on patient-specific characteristics [37].

21. Integration with Artificial Intelligence

Artificial intelligence (AI) and machine learning are increasingly being incorporated into diabetes management.

Applications:

- Predictive glucose monitoring
- Dose optimization
- Risk stratification

AI-driven platforms may enhance the effectiveness of incretin therapies by enabling real-time therapeutic adjustments [38].

22. Expanded Therapeutic Indications

Incretin-based therapies are being investigated beyond diabetes for their systemic benefits.

22.1 Obesity Management

GLP-1 receptor agonists and dual incretin agonists have demonstrated substantial weight reduction, leading to their approval for obesity treatment [39].

22.2 Non-Alcoholic Fatty Liver Disease (NAFLD)

These agents reduce hepatic fat accumulation and inflammation, making them promising candidates for NAFLD and non-alcoholic steatohepatitis (NASH) management [40].

22.3 Cardiovascular Disease
Cardioprotective effects include:
- Reduced atherosclerosis
- Improved endothelial function
- Decreased inflammation

22.4 Neurodegenerative Disorders
Emerging evidence suggests potential neuroprotective effects in:
- Alzheimer's disease
- Parkinson's disease

23. Challenges in Future Development
Despite promising advancements, several challenges remain:
23.1 Cost and Accessibility
High treatment costs limit widespread use, particularly in developing countries.
23.2 Long-Term Safety Data
While short- and medium-term data are encouraging, long-term safety profiles require further investigation.
23.3 Regulatory Challenges
Approval of novel agents, particularly triple agonists, requires extensive clinical validation.

24. Comparative Future Landscape

Therapy	Current Status	Future Potential
GLP-1 RAs	Established	Continued use
Dual agonists	Advanced	Standard therapy
Triple agonists	Emerging	Next-generation
Oral GLP-1	Growing	High adoption

25. DISCUSSION
The introduction of incretin-based therapies has significantly altered the therapeutic paradigm of T2DM. Unlike traditional glucose-lowering agents, these therapies address multiple pathophysiological defects simultaneously, including insulin resistance, impaired insulin secretion, and dysregulated appetite control.

Dual incretin agonists such as tirzepatide have demonstrated superior efficacy in glycemic control and weight reduction compared to GLP-1 receptor agonists and insulin. Furthermore, their cardiovascular and renal benefits provide a comprehensive approach to disease management.

The expanding role of incretin therapies in obesity, liver disease, and neurodegenerative disorders underscores their potential as multifunctional metabolic regulators. However, challenges related to cost, accessibility, and long-term safety must be addressed to ensure broader clinical adoption.

26. CONCLUSION
Incretin-based therapies, particularly GLP-1 receptor agonists and dual incretin agonists, represent a major advancement in the management of type 2 diabetes mellitus. Their ability to target multiple metabolic pathways, combined with favorable safety profiles and additional systemic benefits, positions them as cornerstone therapies in modern diabetes care.

Dual incretin agonists have further enhanced therapeutic outcomes, offering superior glycemic control and weight reduction. The development of triple receptor agonists and non-invasive delivery systems is expected to further revolutionize the field.

Future research focusing on precision medicine, artificial intelligence integration, and expanded therapeutic indications will likely redefine the management of metabolic diseases. Incretin-based therapies are poised to remain at the forefront of diabetes treatment strategies for years to come.

REFERENCES

1. Liu QK, Chen H, Zhang Y. Mechanisms of glucagon-like peptide-1 receptor agonists in metabolic regulation. *Frontiers in Endocrinology*. 2024;15:1298456.
2. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. *StatPearls Publishing*. 2024; Treasure Island (FL):1-25.
3. Ilias I, Valsamakis G, Tsatsoulis A. GLP-1 receptor agonists and their role in diabetes management. *Frontiers in Clinical Diabetes and Healthcare*. 2025;6:1530811.

4. Salvador R, Perez A, Gomez J. Semaglutide in type 2 diabetes: A comprehensive review. *Pharmaceuticals*. 2025;18(3):399-420.
5. Farzam K, Jan A. Tirzepatide: Pharmacology and clinical applications. *StatPearls Publishing*. 2024;1-30.
6. Chuang MH, Lee YH, Lin JW. Comparative effectiveness of incretin-based therapies in type 2 diabetes. *JAMA Network Open*. 2024;7(5):e2412345.
7. Thiriveedi M, Kumar P, Singh A. Clinical efficacy of tirzepatide in obesity and diabetes. *Diabetes Therapy*. 2025;16(2):567-580.
8. Zheng Z, Li X, Wang Y. Cardiovascular effects of GLP-1 receptor agonists: A review. *Signal Transduction and Targeted Therapy*. 2024;9(1):210-225.
9. Yang J, Zhou Y, Chen X. Renal outcomes of incretin-based therapies in diabetes. *Frontiers in Pharmacology*. 2024;15:1453825.
10. Rangraze I, Sharma D, Gupta R. Dual and triple incretin receptor agonists in metabolic diseases. *Expert Opinion on Pharmacotherapy*. 2024;25(12):1456-1470.
11. Sokary S, Ahmed N, Rahman M. Extra-glycemic effects of incretin-based therapies. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2025;19(1):102345.
12. Sehgal NKR, Patel R, Mehta S. Safety and tolerability of GLP-1 receptor agonists: Real-world data. *Diabetes Research and Clinical Practice*. 2026;198:110567.
13. Jastreboff AM, Aronne LJ, Ahmad NN. Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*. 2022;387(3):205-216.
14. Wilding JPH, Batterham RL, Calanna S. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002.
15. Marso SP, Daniels GH, Brown-Frandsen K. Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*. 2016;375(4):311-322.
16. Gerstein HC, Colhoun HM, Dagenais GR. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND trial). *The Lancet*. 2019;394(10193):121-130.
17. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. *Diabetes, Obesity and Metabolism*. 2018;20(S1):5-21.
18. Drucker DJ. Mechanisms of action and therapeutic application of GLP-1. *Cell Metabolism*. 2018;27(4):740-756.
19. Holst JJ. The physiology of glucagon-like peptide-1. *Physiological Reviews*. 2007;87(4):1409-1439.
20. Buse JB, Wexler DJ, Tsapas A. 2022 ADA guidelines for diabetes management. *Diabetes Care*. 2022;45(S1):S125-S143.
21. Davies MJ, D'Alessio DA, Fradkin J. Management of hyperglycemia in type 2 diabetes. *Diabetes Care*. 2018;41(12):2669-2701.
22. Frias JP, Davies MJ, Rosenstock J. Tirzepatide versus semaglutide once weekly (SURPASS-2). *New England Journal of Medicine*. 2021;385(6):503-515.
23. Del Prato S, Kahn SE, Pavo I. Tirzepatide versus insulin degludec (SURPASS-3). *The Lancet*. 2021;398(10300):583-598.
24. Rosenstock J, Wysham C, Frías JP. Tirzepatide versus insulin glargine (SURPASS-4). *The Lancet*. 2021;398(10313):1811-1824.
25. Aroda VR, Ahmann A, Cariou B. Comparative efficacy of tirzepatide and insulin (SURPASS-5). *Diabetes Care*. 2022;45(6):1259-1267.
26. Rubino D, Abrahamsson N, Davies M. Effect of continued weekly semaglutide (STEP-4 trial). *JAMA*. 2021;325(14):1414-1425.
27. Wadden TA, Bailey TS, Billings LK. Effect of semaglutide plus lifestyle intervention (STEP-3). *JAMA*. 2021;325(14):1403-1413.
28. Kushner RF, Calanna S, Davies M. Clinical impact of semaglutide in obesity (STEP-1). *NEJM*. 2021;384:989-1002.
29. Nauck MA, Quast DR, Wefers J. GLP-1 receptor agonists in diabetes and obesity. *The Lancet Diabetes & Endocrinology*. 2021;9(10):653-662.
30. Müller TD, Finan B, Bloom SR. Glucagon-like peptide 1 (GLP-1). *Molecular Metabolism*. 2019;30:72-130.
31. Patel PS, Raval AM, Patel AAAK, Patel PDK, Prajapati TG, Patel PB. A comprehensive review of antibiotic resistance: mechanisms, causes, and novel therapeutic approaches. Asian J Pharm Res Dev. 2026;14(2):117-128.
32. Raval AM, Bhavsar PR, Pandya FU, Patel D. Co-processed excipients in pharmaceutical formulation: advances, characterization, and applications. Asian J Pharm Res Dev. 2026;14(1):105-113. doi:10.22270/ajprd.v14i01.1705.
33. Patel PBK, Raval AM, Patel HB, Patel KH, Patel P, Vaidya PAK, Kahar KH. A comprehensive review of polycystic ovary syndrome (PCOS): pathophysiology, diagnosis and management. *Asian J Pharm Res Dev.* 2026;14(2):32-41. doi:10.22270/ajprd.v14i2.1716.
34. Thakor AD, Dharajiya RM, Shaikh MZ, Raval AM. A review on neuropharmacology: mechanisms, drug classes, and clinical applications. *Asian J Pharm Res Dev.* 2026;14(1):114-121. doi:10.22270/ajprd.v14i01.1709.

35. Raval AM, Rana T, Joshi SY, Buch S, Arora B, Patel VS. Artificial intelligence in pharmacy and healthcare: applications in drug discovery, precision medicine, clinical practice, and future perspectives. *Asian J Pharm Res Dev.* 2026;14(2):62-69. doi:10.22270/ajprd.v14i2.1721.
36. Senjaliya T, Patel M, Raval AM. Strategies for combating the global health threat of antibiotic resistance: novel therapeutics and combination approaches. Asian J Pharm Res Dev. 2026;14(1):122-130. doi:10.22270/ajprd.v14i01.1707.
37. Mevada J, Patel K, Raval AM. Materiovigilance: From device failure to safety reform, the growing importance of materiovigilance systems. Int J Pharm Sci. 2026;4(1):962-74.
38. Falwariya R, Jethva T, Raval AM, Lokhande D. Comprehensive review: Microneedle patches-A painless revolution in transdermal drug delivery. World J Pharm Med Res. 2026;12(1):199-207.
39. Mevada J, Patel K, Raval AM. Role of pharmacovigilance in drug safety monitoring. World J Pharm Med Res. 2025;11(11):235-40.
40. Patel N, Raval AM. Gastro-retentive drug delivery system: A review. Int J Pharm Sci. 2026;4(1):734-42.